German Statutory Reimbursement Listing for NeuroNode
Filed with ASX · · 3 pages · English
Summary by 6ix AI
Control Bionics Ltd. has announced that its NeuroNode device is now included in the German Statutory Health Insurance Medical Aids Directory, confirming its eligibility for reimbursement in Germany's health insurance system. This inclusion is significant as it removes commercial barriers for distributors and validates the device's safety and quality standards. The company plans to appoint a distribution partner, submit pricing applications, and commence pilot installations to accelerate adoption of NeuroNode in Germany. This milestone positions Control Bionics to expand its market presence in Europe and supports its strategy for a NeuroNode-only distribution model.
Written by 6ix AI from the company’s filing. How 6ix writes summaries
Earlier from Control Bionics
- Joint venture with NextLevel Assistive Technology
- Half Yearly Report and Accounts
- PRC-Saltillo - Distribution Agreement
- Quarterly Activities/Appendix 4C Cash Flow Report
- Tobii Dynavox - Distribution Partnership
Later from Control Bionics
- Commercial Momentum Presentation
- Pause in Trading
- Completion of Placement
- Commercial momentum builds across both platform pillars
- US FDA Registration and Device Listing for NeuroStrip
Follow Control Bionics into a list and get an email when it puts out news.
Follow Control Bionics